职务：华南恶性肿瘤防治全国重点实验室分子靶向治疗研究室PI

职称：博士、教授、博士生导师、国家杰出青年科学基金获得者

专长： 肿瘤靶向治疗的基础研究、转化医学研究

　　2006年回国后任华南恶性肿瘤防治全国重点实验室分子靶向治疗实验室主任、中山大学血液病研究所所长等职。刘强教授入选科技部重大科学研究项目(973)首席科学家，教育部“长江学者”特聘教授，国家自然基金委杰出青年基金获得者，科技部中青年科技创新领军人才，教育部创新团队带头人，人社部“百千万人才工程”国家级人选，卫生部“有突出贡献中青年专家”等荣誉称号；兼任中国病理生理学会免疫专业委员会主任委员、中国抗癌协会整合肿瘤分会/肿瘤精准治疗专业委员会/肿瘤转化医学专业委员会副主任委员、中国细胞生物学会肿瘤细胞专业委员会副主任委员、中华医学会理事、中国病理生理学会常务理事、美国医学及生物工程院(AIMBE)Fellow、美国中华医学基金会(CMB)杰出教授。作为首席科学家承担973项目、国自然重点项目等基金项目，并获得华夏医学科技奖、中国抗癌协会科技奖等科技奖励。围绕肿瘤靶向治疗的转化医学研究，刘强教授先后在Nat Med、J Clin Oncol、Cell Res、Nat Commun、J Clin Invest、Cancer Cell、PNAS、Blood、Autophagy等国际知名学术期刊发表论著120余篇，获得授权发明专利5项。

研究方向：

1. 神经及免疫在肿瘤干细胞中的作用及机制研究

2. 肿瘤干细胞可塑性信号网络与干预研究        

3. 肿瘤干细胞表观遗传及分化诱导治疗

教育经历

1985年毕业于南京大学

留学经历

1997年毕业于美国伊利诺大学香槟分校，获免疫学博士学位

2000年毕业于美国伊利诺大学芝加哥分校，获临床医学博士学位

主持的主要科研项目

1. 国家重点研发计划，2019YFA0110303，免疫分子及细胞对神经干细胞增殖与分化的调控机制(课题三)，2019-2023 

2. 国家重点研发计划，2017YFA0505600-04，基于基因组不稳定性的新型蛋白质机器在肿瘤发生发展中的作用、机制及干预（课题四），2017-2022 

3. 广州市科技计划重点项目，201804020044，核转位蛋白激酶Aurora-A调控肿瘤干性的非经典机制及干预研究，2018-2021 

4. 国家自然科学基金重点国际(地区)合作研究项目，81820108024，蛋白激酶AURKA核转位调控肿瘤干性的非经典机制及干预研究，2019-2023 

5. 创新团队发展计划滚动支持，IRT-17R15，肿瘤干细胞的信号网络干预，2018-2020

6. 国家自然科学基金重点项目，81630005，基于Aurora A激酶“一靶双点”的髓系白血病靶向治疗新策略，2017-2021

7. 国家自然科学基金面上项目，81573025，基于微流控芯片研究靶向AURKA治疗中肿瘤微环境的作用及其机制，2016-2019 

8. 创新团队发展计划，IRT13049，肿瘤干细胞的信号网络干预，2014-2016 

9. 国家重大科学研究计划(973)，2012CB967000，肿瘤干细胞的动态演进及干预研究，2012-2016 

10. 国家自然科学基金重点项目，81130040，肿瘤分子靶向治疗产生多倍体的耐药机制，2012-2016 

11. “973”项目子课题，2011CB504305，致瘤病毒及细胞内信号通路靶向治疗的基础研究，2011-2015 

代表性论文

1. Liu F, Wang X, Duan J, Hou Z, Wu Z, Liu L, Lei H, Huang D, Ren Y, Wang Y, Li X, Zhuo J, Zhang Z, He B, Yan M, Yuan H, Zhang L, Yan J, Wen S*, Wang Z*, Liu Q*.A Temporal PROTAC Cocktail-Mediated Sequential Degradation of AURKA Abrogates Acute Myeloid Leukemia Stem Cells. Adv Sci (Weinh). 2022 Aug;9(22):e2104823. 

2. Li S, Qi Y, Yu J, Hao Y, He B, Zhang M, Dai Z, Jiang T, Li S, Huang F, Chen N, Wang J, Yang M, Liang D, An F, Zhao J, Fan W, Pan Y, Deng Z, Luo Y, Guo T, Peng F, Hou Z, Wang C, Zheng F, Xu L, Xu J, Wen Q, Jin B*, Wang Y*, Liu Q*.Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4. Signal Transduct Target Ther. 2022 Apr 1;7(1):97.

3. Cai W, Hu M, Li C, Wu R, Lu D, Xie C, Zhang W, Li T, Shen S, Huang H, Qiu W, Liu Q*, Lu Y*, Lu Z*.FOXP3+ macrophage represses acute ischemic stroke-induced neural inflammation. Autophagy. 2022 Sep 28:1-20.

4. An F, Hou Z, Wang X, Wang Z, Jing C, Sui R, Wu Y, Ma Y, Chang C, Liu S, Li M, Sun L, Gao Z, Zhang W, Lang Z, Zhao J, Qu Y, Xu L, Luo Y, Yan J, Wang Y, Xu J*, Liu Q*. A microfluidic demonstration of "cluster-sprout-infiltrating" mode for hypoxic mesenchymal stem cell guided cancer cell migration. Biomaterials. 2022 Nov;290:121848. 

5. Xie J, Wang Z, Fan W, Liu Y, Liu F, Wan X, Liu M, Wang X, Zeng D, Wang Y, He B, Yan M, Zhang Z, Zhang M, Hou Z, Wang C, Kang Z, Fang W, Zhang L, Eric W-F Lam, Guo X, Yan J, Zeng Y, Chen M,  Liu Q*. Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiationin nasopharyngeal carcinoma. Signal Transduct Target Ther. 2021, 6(1): 333-349

6. Chen A, Wen S, Liu F, Zhang Z, Liu M, Wu Y, He B, Yan M, Kang T, Lam EW, Wang Z, Liu Q*. CRISPR/Cas9 screening identifies a kinetochore-microtubule dependent mechanism for Aurora-A inhibitor resistance in breast cancer. Cancer Commun. 41, 121–139 (2021).

7. Cui B, Peng F, Lu J, He B, Su Q, Luo H, Deng Z, Jiang T, Su K, Huang Y, Ud Din Z, Lam EW, Kelley KW, Liu Q*. Cancer and stress: NextGen strategies. Brain, Behavior, and Immunity vol. 93 368–383 (2021).

8. Peng F, Xu J, Cui B, Liang Q, Zeng S, He B, Zou H, Li M, Zhao H, Meng Y, Chen J, Liu B, Lv S, Chu P, An F, Wang Z, Huang J, Zhan Y, Liao Y, Lu J, Xu L, Zhang J, Sun Z, Li Z, Wang F, Eric W.-F. Lam, Liu Q*. Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2021, 31, 345-361.

9. Cui B, Luo YY, Tian PF, Peng F, Yang YL, Lu JX, Su QT, Yu JC, Yin L, Cheng W, Xu J, An F,He B, Liang DP, Wu SJ, Chu P, Song LY, Liu XY, Luo HD, Pan YJ, Wang Y, Li DS, Huang P, Yang QK, Xu GW, Zhang LQ, Zhou P, Liu SL, Eric L, Kelley KW, Liu Q*. Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells. J Clin Invest. 2019 Mar 1;129(3):1030-1046.

10. Wen HJ, Ma HJ, Cai QC, Lin SX, Lei XX, He B, Wu SJ, Wang ZF, Gao Y, Liu WS, Liu WP, Tao Q, Long ZJ, Yan M, Li DL, Kelley KW, Yang YL, Huang HQ, Liu Q*. Recurrent ECSIT V140A Mutation Triggers Hyperinflammation and Promotes Hemophagocytic Syndrome in Extranodal NK/T-Cell Lymphoma. Nat Med. 2018, 24(2):154-164.

11. Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, Kang ZJ, Fan WJ, Zhu LL, Li M, Cui B, Zheng FM, Wang HJ, Lam EW, Wang B, Xu J*, Liu Q*. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. Oncogene. 2018, 37(8):1062-1074.

12. Yang N, Wang C, Wang Z, Zona S, Lin SX, Wang X, Yan M, Zheng FM, Li SS, Xu B, Bella L, Yong JS, Lam EW* and Liu Q*, FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene, 2017. 36(24): p. 3428-3440.

13. Lyu Y, Lou J, Yang Y, Feng J, Hao Y, Huang S, Yin L, Xu J, Huang D, Ma B, Zou D, Wang Y, Zhang Y, Zhang B, Chen P, Yu K, Lam EW, Wang X, Liu Q*, Yan J*, Jin B*. Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways. Leukemia. 2017, 31(12):2543-2551.

14. Zheng F, Yue C, Li G, He B, Cheng W, Wang X, Yan M, Long Z, Qiu W, Yuan Z, Xu J, Liu B, Shi Q, Lam EW, Hung MC, Liu Q*. Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun. 2016;7:10180.

15. Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM, Xu J, Chen MY, Zhu YL, Wen HJ, Wan XB, Yue CF, Yang N, Zhang W, Zhang JL, Wang J, Wang Y, Li LH, Zeng YX, Lam EW, Hung MC and Liu Q*, IKKalpha restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun, 2014. 5: p. 3661.

16. Guan Z, Zhang J, Wang J, Wang H, Zheng F, Peng J, Xu Y, Yan M, Liu B, Cui B, Huang Y and Liu Q*, SOX1 down-regulates beta-catenin and reverses malignant phenotype in nasopharyngeal carcinoma. Mol Cancer, 2014. 13: p. 257.

17. Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q, Dominguez D and Wang Z, The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell, 2014. 26(3): p. 374-389.

18. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, Zhu Y, Chen S, Xu J, Yan M, Wang J and Liu Q*, Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy, 2012. 8(12): p. 1798-810.

19. Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, Ding YG, Wan XB, Guan Z, Li HG, Lin DJ, Shao CK and Liu Q*, Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer. Autophagy, 2012. 8(3): p. 389-400.

20. Wang J, Han F, Wu J, Lee SW, Chan CH, Wu CY, Yang WL, Gao Y, Zhang X, Jeong YS, Moten A, Samaniego F, Huang P, Liu Q, Zeng YX and Lin HK, The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood, 2011. 118(20): p. 5429-38.

21. Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y, Yue CF, Xu J, Zheng FM, Chen JN, Kang Z, Chen TS, Xing D and Liu Q*, The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res, 2010. 70(22): p. 9118-28.

22. Wan XB, Fan XJ, Chen MY, Xiang J, Huang PY, Guo L, Wu XY, Xu J, Long ZJ, Zhao Y, Zhou WH, Mai HQ, Liu Q* and Hong MH*, Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy, 2010. 6(3): p. 395-404.

23. Xu J, Wan XB, Huang XF, Chan KC, Hong MH, Wang LH, Long ZJ, Liu Q, Yan M, Lo YM, Zeng YX and Liu Q*, Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol, 2010. 28(35): p. 5202-9.

24. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G, Liu Q, Pei D, Kang T and Zeng YX, Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem, 2010. 285(7): p. 4931-40.

25. Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu Q, Huang WL, Zeng YX and Zhu XF, The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009. 28(6): p. 886-98.

26. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH, Yan M, Wang XR, Wan XB, Zheng FM, Zeng YX and Liu Q*, Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood, 2008. 111(5): p. 2854-65.

27. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, Huang W, Zeng YX, Chen FJ and Liu Q*, Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res, 2007. 67(21): p. 10436-44.

28. Liu Q and Ruderman JV, Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A, 2006. 103(15): p. 5811-6.

29. Liu Q, Vanhoy RW, Zhou JH, Dantzer R, Freund GG and Kelley KW, Elevated cyclin E levels, inactive retinoblastoma protein, and suppression of the p27(KIP1) inhibitor characterize early development of promyeloid cells into macrophages. Mol Cell Biol, 1999. 19(9): p. 6229-39.

30. Liu Q, Ning W, Dantzer R, Freund GG and Kelley KW, Activation of protein kinase C-zeta and phosphatidylinositol 3'-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J Immunol, 1998. 160(3): p. 1393-401.

31. Liu Q, Schacher D, Hurth C, Freund GG, Dantzer R and Kelley KW, Activation of phosphatidylinositol 3'-kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes. J Immunol, 1997. 159(2): p. 829-37.

32. Liu Q, Arkins S, Biragyn A, Minshall C, Parnet P, Dantzer R and Kelley KW, Competitive reverse transcriptase-polymerase chain reaction using a synthetic internal RNA standard to quantitate transcripts for leukocyte-derived hormones. Neuroimmunomodulation, 1994. 1(1): p. 33-41.